Understanding mechanisms of reduced cefiderocol susceptibility in <i>pvdS</i> and <i>fecI</i> mutants of <i>Pseudomonas aeruginosa</i>

These data highlight different mechanisms by which P. aeruginosa attempts to evade the action of cefiderocol by exploiting the complexities of iron haemostasis in bacteria. The absence of such mutants in the clinic suggests that such mutations may be detrimental for P. aeruginosa to survive in the clinical environment.